A simple, precise, reproducible and accurate spectrofl uorimetric method for estimation of Salbutamol sulphate (SAL) in bulk drug and various dosage forms has been developed. This method is based on formation of inclusion complex of SAL in β-cyclodextrin (BCD) which gives fl uorescence at excitation wavelength of 279.6 nm and emission wavelength of 609.8 nm in water. Formation of inclusion complex of drug with BCD enhances fl uorescence intensity of drug leads to increased sensitivity. The developed method was validated according to ICH guidelines with respect to accuracy, precision, linearity, limit of detection, limit of quantifi cation. Linearity was observed in the range of 4-20 μg/ ml with correlation coeffi cient of 0.9982. The simplicity of the method permitt ed rapid analysis suitable for routine control. The developed method was successfully applied for the estimation of SAL in diff erent marketed dosage forms like tablets, syrup and aerosol.
INTRODUCTION
Salbutamol Sulphate (SAL) is chemically (RS)-1-(4-hydroxy-3-hydroxy methyl phenyl)-2-(tert-butyl amino) ethanol sulphate. It is β 2 -adrenoceptor agonist very widely used as bronchodilator in the treatment of asthma and seasonal allergies. [1] SAL is offi cial in IP, BP and USP [2] [3] [4] and the offi cial method for quantifi cation of SAL bulk drug is non-aqueous titration, while for syrup and injection dosage form, colorimetric method is employed. Electrochemical techniques, [5] [6] [7] chromatographic methods, [8] [9] [10] spectrophotometric methods [11] [12] [13] [14] [15] and automated methods such as fl ow injection analysis [16, 17] are also reported for detection of SAL in bulk drug and pharmaceutical formulation. The reported chromatographic methods for estimation of SAL are time consuming while offi cial electrochemical and colorimetric methods are less selective and sensitive. Literature survey revealed that diff erent analytical methods are available for estimation of SAL from diff erent marketed formulations. Hence the aim of the research work is to develop a single analytical method applicable for estimation of SAL in various marketed formulations. The present research article describes the development and validation of spectrofl uorimetric method for SAL using β-cyclodextrin (BCD) as an inclusion complex. The developed method was validated and was extended for the estimation of SAL in diff erent pharmaceutical formulations.
MATERIALS AND METHODS

Materials and chemicals
Pure sample of SAL and BCD was gift ed from Barouq Pharmaceuticals Ltd.
(Anand, India) and Roquett e Ltd. (Mumbai, India), respectively. The pharmaceutical formulations of SAL like tablets, syrup and aerosol (all with brand name ASTHALIN, Cipla Pharmaceuticals Ltd. India) were purchased from local market. Sulphuric acid (98%), ethanol, diethyl ether and dimethylsulphoxide (DMSO) were used of analytical grade. Distilled water was used throughout the study.
Instrument
Spectrofl uorimetric measurements were carried out using Spectrofl uorometer FP 6500 with 1 cm quartz cell (JASCO Corporation, Japan).
Analytical methodology for estimation of SAL in Pharmaceutical Formulations
Standard preparation SAL (20 mg) was accurately weighed and transferred into 200 ml volumetric fl ask and diluted up to mark with water. An aliquot (1 ml) was further diluted with water in 10 ml volumetric fl ask, to obtain fi nal concentration 10 μg/ml. BCD (50 mg) was weighed accurately and transfer into 50 ml volumetric fl ask and diluted up to mark with water to obtain concentration 1 mg/ml.
Preparation of inclusion complex
Accurately weighed 20 mg of SAL was dissolved in 5 ml of DMSO. BCD solution (1 mg/ml) was added with continuous agitation to prepare diff erent ratios of SAL: BCD in diff erent proportion from 1: 0.5 to 1: 2.0, it was then diluted with water to obtain concentration of 100 μg/ml SAL in BCD inclusion complex. An aliquot (1ml) was further diluted with water in 10 ml volumetric fl ask to obtain fi nal concentration 10 μg/ml.
Spectrofl uorometric determination
For selection of excitation and emission wavelength of inclusion complex, excitation spectra was scanned between 220-400 nm, while emission spectra was scanned between 400-700 nm. The wavelengths selected for analysis was 279.6 nm as excitation wavelength and 609.8 nm as emission wavelength. Fluorescence intensity of standard and sample solutions determined at selected excitation and emission wavelength.
Sample preparation
Tablet dosage form Twenty tablets were weighed and crushed. Tablet powder equivalent to 20 mg of SAL was accurately weighed and transferred to volumetric fl ask; 10 ml water was added into crushed powder and was sonicated for 20 minutes. Above solution was fi ltered using whatman fi lter paper 41. Filtrate was collected in crucible and was allowed to evaporate in vacuum dryer until the constant weight was obtained. Collected dry powder was dissolved in 5 ml DMSO and mixed with BCD solution (1 mg/ml, 24 ml) with continuous agitation and kept aside for 20 min and diluted up to 250 ml with water. An aliquot was further diluted with water to obtain fi nal concentration 9.6 μg/ml.
Syrup dosage form
Ten ml of syrup containing 4 mg of SAL was accurately pipett ed out and mixed with 25 ml 0.05 M H 2 SO 4 . Aqueous solution was extracted twice with 50 ml diethyl ether. Aqueous extract was collected in 250 ml volumetric fl ask. Ether extract was washed with 10 ml water. All aqueous extract was collected together and passed through charcoal to remove coloring matt er. DMSO (5 ml) was added in aqueous solution and then BCD solution (1mg/ml, 4.8 ml) was added with continuous agitation and kept aside for 20 min. Volume was adjusted upto the mark with water in 250 ml volumetric fl ask. An aliquot was further diluted with water to obtain fi nal concentration 9.6 μg/ml.
Aerosol dosage form
For assay of SAL from aerosol dosage form (200 μg/dose), pressurized container removed from the actuator. All the labels and markings present on the container were removed with a suitable solvent. Container was placed in the plastic bag and cooled at least -20  C for 24 hrs in deep freezer. Small hole was carefully pierced on the shoulder of the container. Propellant was allowed to evaporate (about 3 hrs) and then top was removed. The top and valve of the open container were washed with litt le ethanol. All the component of the container put in ethanol (about 20 ml) and sonicated for 15 minutes. Combined alcoholic extract was evaporated into vacuum dryer to obtained constant weight. Collected dry powder was dissolved in 5 ml DMSO and further treated same as given under tablet dosage form to prepare inclusion complex and further diluted to prepare fi nal concentration 9.6 μg/ml.
Sample solutions of all pharmaceutical formulations of SAL were analysed as described under spectrofl uorometric determination.
Method validation
The developed method was validated in terms of linearity, limit of detection (LOD), limit of quantifi cation (LOQ), precision and accuracy.
For linearity and range, SAL: BCD inclusion complex (1:1) was prepared in concentration range of 4-20 μg/ ml and then fl uorescence intensity of the prepared samples was measured.
The LOD and LOQ were determined from the slope values and standard deviation of intercept of linearity study.
The precision study was performed by intraday and interday precision, where analytical experiment was repeated three times in a day and on three diff erent days using three diff erent concentrations (2, 8, 15 μg/ ml) and the results were evaluated for RSD of the assay results obtained in the two conditions.
Accuracy of the method was evaluated by recovery study where standard SAL solution was spiked at three diff erent levels (80 %, 100 % and 120 %) and the amount recovered was found out.
RESULTS AND DISCUSSION
Method development SAL is freely soluble in water but it gives very less . Literature survey revealed that BCD forms inclusion complex with benzene derivatives and decreases quenching eff ect. [18] Formation of inclusion complex of SAL with BCD did not show any signifi cant wavelength shift but it enhanced peak intensity. This may be because the hydrophobic cavity of BCD increases solubility, decrease quenching eff ect and improve fl uorescence intensity; hence BCD was choosen as complexing agent in this experiment. Diff erent complexation methods were used to prepare SAL: BCD inclusion complex. The inclusion complex ratio was also optimized and it was observed that 1:1 ratio of SAL and BCD gave maximum fl uorescence intensity [ Figure 2 ]. From the scanned spectra it was observed that SAL gives maximum absorbance at 279.6 nm as excitation wavelength and emission wavelength observed was 609.8 nm [ Figures 3a and b] .
Method validation
The developed method was validated for linearity and range, precision, LOD, LOQ, accuracy as per ICH guidelines for analytical method validation. [19] The SAL: BCD inclusion complex showed linear response in the concentration range of 4-20 μg/ml with good correlation coeffi cient (r) value of 0.9982. Similarly the method showed good precision when it was performed on the diff erent intervals on same day (% RSD 0.67) and on diff erent days (% RSD 1.16). The results of linearity, LOD, LOQ and precision study are given in table 1. The 0.9982 Intra-day precision (RSD) (n = 3) 0.67% Inter-day precision (RSD) (n = 3)
1.16% LOD (μg/ml) 0.60 LOQ (μg/ml) 1.81 accuracy study was performed by standard addition method. Table 2 shows the percentage of drug recovered (98.52-101.45%) which was in good agreement with the added amount and label claim. Recovery experiment indicated the absence of interference from commonly encountered pharmaceutical additives and excipients.
Method application
Diff erent types of marketed formulations of SAL are available and according to that sample preparation can vary for estimation. Initially IP procedure was followed for sample preparation [2] and modifi cation were incorporated as per developed method requirement. Assay results of SAL in all formulations are summarized in Table 3 . The obtained results, indicates that the developed and validated method can be successfully applied for estimation of SAL from all type of marketed formulations like tablet, syrup and aerosol.
CONCLUSION
Drugs which show fl uorescent quenching in aqueous solutions can be analyzed easily by preparing inclusion complex with BCD. The proposed and developed spectrofluorimetric method is simple, specifi c, accurate, precise, economical and rapid. The developed method allowed estimation of SAL from different marketed pharmaceutical dosage forms like tablet, syrup and aerosol without interference. The proposed procedure is useful for routine quality control of SAL in diff erent pharmaceutical dosage forms. 
